ORIFARM GENERICS A/S: Financial statements 2019
CVR: 25674030
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 545,016,000 and a net result of DKK 103,855,000 compared with DKK 70,055,000 the year before. That is an increase of 8% compared with the year before. The profit margin was 19.1%. Equity in the 2019 report amounted to DKK 145,680,000. The solvency ratio was 44.1%. The company had 99 employees in the financial year.
- Revenue
- DKK 545,016,000
- Gross Profit
- DKK 197,046,000
- Profit/Loss
- DKK 103,855,000
- Equity
- DKK 145,680,000
- Total Assets
- DKK 330,196,000
- Employees
- 99
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 545 mio. | 197 mio. | 103.9 mio. | 145.7 mio. | 99 |
| 2018 | 504.4 mio. | 162.7 mio. | 70.1 mio. | 116.8 mio. | 102 |
| 2017 | - | 172 mio. | 76.4 mio. | 86.8 mio. | 97 |
| 2016 | - | 169.9 mio. | 83.3 mio. | 60.4 mio. | 78 |
| 2015 | - | 40 mio. | 605 t. | 8 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
ORIFARM GENERICS A/S has published its annual report for 2018. Revenue came to DKK 504,442,000, and the net result was DKK 70,055,000.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.